- In February 2026, iRhythm Holdings reported Q4 2025 results showing sales of US$208.89 million and a return to quarterly profitability, while full-year 2025 revenue reached US$747.14 million with a reduced annual net loss.
- The company also issued 2026 revenue guidance of US$870 million to US$880 million and highlighted expansion plans, AI-enabled product development, and international growth initiatives as it works to improve efficiency and broaden its cardiac monitoring platform.
- We’ll now examine how iRhythm’s stronger Q4 profitability and higher 2026 revenue outlook may influence the existing investment narrative.
We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
iRhythm Holdings Investment Narrative Recap
To own iRhythm, you generally need to believe its Zio cardiac monitoring platform and AI tools can gain wider clinical adoption while the company steadily improves profitability. The Q4 return to positive earnings and higher 2026 revenue guidance support that thesis, but also highlight that the key near term catalyst is sustained margin improvement. The biggest current risk remains execution and cost control as the business scales; this earnings print does not remove that concern.
The most relevant recent development is the 2026 revenue outlook of US$870 million to US$880 million, which sets a higher bar for growth and operational delivery after a stronger Q4. That guidance now sits alongside ongoing investments in AI enabled products and international expansion, making future quarters’ progress on operating margins and cash generation particularly important for how investors judge the balance between growth and financial discipline.
Yet despite this improving profitability story, investors still need to be aware that regulatory and reimbursement pressures could...
Read the full narrative on iRhythm Holdings (it's free!)
iRhythm Holdings' narrative projects $1.1 billion revenue and $49.7 million earnings by 2028. This requires 17.5% yearly revenue growth and a $142.1 million earnings increase from $-92.4 million today.
Uncover how iRhythm Holdings' forecasts yield a $221.27 fair value, a 57% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span a wide range, from US$74.68 to US$236.02 per share. Against that backdrop, the recent return to quarterly profitability and higher 2026 revenue guidance may influence how you weigh growth potential against execution and cost control risks.
Explore 3 other fair value estimates on iRhythm Holdings - why the stock might be worth as much as 67% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your iRhythm Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free iRhythm Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate iRhythm Holdings' overall financial health at a glance.
Seeking Other Investments?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com